Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma

Molecular Cancer Therapeutics

Volumn 11, Issue 4, 2012, Pages 942-951

  McMillin, Douglas W ^a   Jacobs, Hannah M ^a   Delmore, Jake E ^a   Buon, Leutz ^a   Hunter, Zachary R ^a   Monrose, Val ^a   Yu, Jie ^b   Smith, Peter G ^b   Richardson, Paul G ^a   Anderson, Kenneth C ^a   Treon, Steven P ^a   Kung, Andrew L ^a   Mitsiades, Constantine S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[4 [4 [(2,3 DIHYDRO 1H INDEN 1 YL)AMINO] 7H PYRROLO[2,3 D]PYRIMIDIN 7 YL] 2 HYDROXYCYCLOPENTYLMETHYL] SULFAMATE; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; NEDD8 PROTEIN; PROTEASOME; SYNDECAN 1; UBIQUITIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MALE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOCLAST; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TUMOR VOLUME; UPREGULATION;

ANIMALS; BORONIC ACIDS; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MULTIPLE MYELOMA; PYRAZINES; TREATMENT OUTCOME; UBIQUITIN-ACTIVATING ENZYMES; UBIQUITINATION; UBIQUITINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862637714     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0563     Document Type: Article

References (20)

1. Soucy TA, Smith PG, Rolfe M. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res 2009;15:3912-6.
2. Soucy TA, Dick LR, Smith PG, Milhollen MA, Brownell JE. The NEDD8 conjugation pathway and its relevance in cancer biology and therapy. Genes Cancer 2010;1:708-16.
3. DSMZ. Available from: http://www.dsmz.de/
4. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 2009;458:732-6.
5. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22. (Pubitemid 29269108)
6. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98. (Pubitemid 41007864)
7. Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, et al. Gene expression profiling and correlationwith outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007;109:3177-88. (Pubitemid 46572502)
8. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001;98:795-804.
9. McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S, et al. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med 2010;16:483-9.
10. Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L, et al. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood 2010;116:1515-23.
11. Mitsiades CS, Mitsiades NS, Bronson RT, Chauhan D, Munshi N, Treon SP, et al. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res 2003;63:6689-96. (Pubitemid 37322948)
12. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002;99:14374-9. (Pubitemid 35257679)
13. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A 2004;101:540-5. (Pubitemid 38084672)
14. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy formultiplemyeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004;5:221-30. (Pubitemid 38402114)
15. Gene Expression Omnibus. Available from: http://www.ncbi.nlm.nih.gov/geo/
16. Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007;109:1692-700. (Pubitemid 46239604)
17. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood 2006;108:2020-8. (Pubitemid 44395016)
18. Mattioli M, Agnelli L, Fabris S, Baldini L, Morabito F, Bicciato S, et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 2005;24:2461-73. (Pubitemid 40593037)
19. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006;9:313-25.
20. Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, et al. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 2010;115:3796-800.